Acute Myeloid Leukemia, Adult Clinical Trial
Official title:
Retrospective, Observational, Monocentric Study to Assess Efficacy and Safety of the Combination of an Hypomethylating Agent in Combination With Venetoclax for Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy
This is a retrospective, observational, monocentric study to evaluate the efficacy and safety of the combination of an hypomethylating agent with venetoclax newly diagnosed patients with acute myeloid leukemia ineligible for intensive chemotherapy
The prognosis of acute myeloid leukemia (AML) patients who are ineligible for intensive
chemotherapy is poor (Kantarjian et al). Hypomethylating agents, azacitidine and decitabine,
are effective and less toxic regimens, and treatment with these agents has improved the
prognosis of these patients (Fenaux et al).
Venetoclax, a Bcl-2 inhibitor, in combination with azacitidine has shown efficacy in AML
patients with complete remission rate of 73% and overall survival at 2 years of 40-50% (Di
Nardo et al).
On these grounds, the aim of this study is to collect the real-life experience with this
combination in previously untreated AML patients.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05133882 -
A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05601726 -
First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients
|
Phase 1 | |
| Recruiting |
NCT06200441 -
Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Markers in Graft-Versus-Host Disease
|
||
| Recruiting |
NCT04050280 -
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
|
Phase 2 | |
| Recruiting |
NCT06449482 -
Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06252584 -
Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients
|
Phase 1 | |
| Completed |
NCT05988047 -
Analysis of CMTM6 Expression in Patients With Acute Myeloid Leukemia
|
||
| Terminated |
NCT03951961 -
Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation
|
Phase 2 | |
| Enrolling by invitation |
NCT03902665 -
Up-front Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged 65-75
|
Phase 2 | |
| Not yet recruiting |
NCT06285136 -
Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05127798 -
RWE of 1st Line Treatment in Adults With AML From 18 to 70 Years Old.
|
||
| Recruiting |
NCT05906914 -
Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia
|
Phase 2 | |
| Not yet recruiting |
NCT06199557 -
A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04752527 -
Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features
|
Phase 2 | |
| Recruiting |
NCT03766126 -
Lentivirally Redirected CD123 Autologous T Cells in AML
|
Phase 1 | |
| Recruiting |
NCT05674539 -
Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
|
Phase 3 | |
| Enrolling by invitation |
NCT02985372 -
Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia
|
Phase 3 | |
| Recruiting |
NCT05703126 -
Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML
|
N/A | |
| Recruiting |
NCT04240600 -
Effect of a Hyperproteic Hyperenergetic Enteral Formula on Body Composition and VEGF in AML During Hospital Stay
|
N/A | |
| Terminated |
NCT04425655 -
Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.
|
Phase 2 |